MXPA05010859A - Antagonistas mchr1 heterociclicos. - Google Patents

Antagonistas mchr1 heterociclicos.

Info

Publication number
MXPA05010859A
MXPA05010859A MXPA05010859A MXPA05010859A MXPA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A MX PA05010859 A MXPA05010859 A MX PA05010859A
Authority
MX
Mexico
Prior art keywords
heterocyclic
mchr1 antagonists
mchr1
antagonists
11cby
Prior art date
Application number
MXPA05010859A
Other languages
English (en)
Inventor
Huiqiang Zhou
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MXPA05010859A publication Critical patent/MXPA05010859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Abstract

Esta invencion se refiere a nuevos heterociclos los cuales son antagonistas en el receptor de hormona concentradora de melanina (MCHR1), tambien referido como 11CBy, a composiciones farmaceuticas que los contienen, a procesos para su preparacion, y a su uso en medicinas. Los compuestos de la invencion tienen la formula (I).
MXPA05010859A 2003-04-11 2004-04-06 Antagonistas mchr1 heterociclicos. MXPA05010859A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46229203P 2003-04-11 2003-04-11
PCT/US2004/010518 WO2004092181A1 (en) 2003-04-11 2004-04-06 Heterocyclic mchr1 antagonists

Publications (1)

Publication Number Publication Date
MXPA05010859A true MXPA05010859A (es) 2005-12-14

Family

ID=33299933

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010859A MXPA05010859A (es) 2003-04-11 2004-04-06 Antagonistas mchr1 heterociclicos.

Country Status (8)

Country Link
US (1) US20060194871A1 (es)
EP (1) EP1618112A1 (es)
JP (1) JP2006522812A (es)
AR (1) AR044011A1 (es)
CA (1) CA2521832A1 (es)
MX (1) MXPA05010859A (es)
TW (1) TW200510429A (es)
WO (1) WO2004092181A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1876179B1 (en) * 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
WO2007011285A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
CA2623541A1 (en) * 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. Method for 1h-imidazo[4,5-c]pyridines and analogs thereof
CA2623722A1 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
TW200800908A (en) * 2006-02-15 2008-01-01 Sanofi Aventis Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
US8263772B2 (en) * 2006-06-08 2012-09-11 Eli Lilly And Company MCH receptor antagonists
BRPI0712684A2 (pt) * 2006-06-08 2012-06-19 Lilly Co Eli antagonistas do receptor do mch
WO2008002575A1 (en) * 2006-06-26 2008-01-03 The Procter & Gamble Company Melanin concentrating hormone antagonists
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
WO2008020799A1 (en) * 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
MX2009007337A (es) 2007-01-10 2009-07-15 Albany Molecular Res Inc Indazoles sustituidos con 5-piridinona.
JP5514716B2 (ja) * 2007-05-11 2014-06-04 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
NZ582586A (en) 2007-07-21 2011-12-22 Albany Molecular Res Inc 5-pyridinone substituted indazoles
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
JPWO2013168759A1 (ja) * 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
KR101551313B1 (ko) * 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
AU2015295248B2 (en) * 2014-07-31 2019-05-16 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors
CN106866545B (zh) * 2017-03-31 2019-07-09 枣庄学院 1-环烷烃-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407149C (en) * 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP2004504303A (ja) * 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
US20060194871A1 (en) 2006-08-31
AR044011A1 (es) 2005-08-24
CA2521832A1 (en) 2004-10-28
JP2006522812A (ja) 2006-10-05
TW200510429A (en) 2005-03-16
WO2004092181A1 (en) 2004-10-28
EP1618112A1 (en) 2006-01-25
WO2004092181A9 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
MY137535A (en) New pyrrolidinium derivatives
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
TW200613243A (en) Novel compounds
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
DE60205234D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
MX2007010414A (es) Derivados de piridin-2-carboxamida como antagonistas de mglur5.
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
MXPA05011243A (es) Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors